Drugs / Pregabalin
Pregabalin
also known as
Lyrica · PGB · CI-1008 · PGL · GLA5PR GLARS-NF1 · S+ 3-isobutyl GABA · YHD1119 · averopreg · +18 more
Regulatory milestones approvals, filings & regulatory actions · 9 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed neuropathy, painful 1 milestone | |||||
| Filed | Japan (PMDA) | — | neuropathy, painful | 2009-09-25 | “Pfizer launched pregabalin in the U.S. and Europe with the brand name, Lyrica® and has filed a New Drug Application (NDA) in Japan.” eisai.com ↗ |
| Approved Indication not stated 3 milestones | |||||
| Label expansions (6) | US (FDA) | LYRICA | — | 2007-06-21 – 2019-05-23 | fda.gov ↗ |
| Approved | US (FDA) | LYRICA | — | 2004-12-30 | fda.gov ↗ |
| Approved | EU (EMA) | Lyrica | — | 2004-07-05 | europa.eu ↗ |
Trials 312 · started per year
today
EU approved 2004
US approved 2004
1
2
2
4
4
6
17
18
21
18
19
20
22
14
10
14
11
10
7
8
8
11
11
10
7
14
8
14
19971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 06 trials | ||||||
| Phase 0 | NCT06600607 | Oct 2024 | — | Latigo Biotherapeutics | Completed | No outcome recorded |
| Phase 0 | NCT05292066 | Oct → Dec 2022 | neuropathy, painful | Aga Khan University | Unknown | No outcome recorded |
| Phase 0 | NCT04648540 | Dec 2020 → Aug 2022 | — | Cairo University | Completed | No outcome recorded |
| Phase 0 | NCT01511640 | Feb 2017 → Mar 2020 | substance-related disorder | University of Kentucky | Completed | No outcome recorded |
| Phase 0 | NCT00644137 | Aug 2007 → Feb 2010 | nicotine dependence | Yale University | Completed | No outcome recorded |
| Phase 0 | NCT00583869 | May 2007 → Aug 2009 | — | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 134 trials · 1 met primary · 1 missed | ||||||
| Phase 1 | NCT07618715 | Jun → Aug 2026 overdue | — | Neurodawn Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07013773 | May → Jul 2025 overdue | — | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT06935721 | Mar → May 2025 overdue | — | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT06935682 | Jan → May 2025 overdue | — | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT06512155 | Jul → Nov 2024 | sleep disorder | Mengchang Yang | Completed | No outcome recorded |
| Phase 1 | NCT06077786 | Oct 2023 → May 2024 | — | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 1 | NCT04265456 | Jan → Jun 2020 | — | Nevakar, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05370716 | Nov 2019 → Apr 2020 | — | CrystalGenomics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03191136 | May → Jun 2017 | neuropathy, painful | Yuhan Corporation | Completed | No outcome recorded |
| Phase 1 | NCT03618589 | Nov 2016 → Dec 2019 | neuropathy, painful | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT02783183 | Jun → Aug 2016 | neuropathy, painful | Yuhan Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02725112 | Feb → May 2016 | — | Viatris Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02783638 | Jan → Apr 2016 | neuropathy, painful | Yuhan Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02349607 | Jan → Mar 2015 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02327000 | Oct 2014 | — | GL Pharm Tech Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01638273 | Feb → Jul 2014 | — | GL Pharm Tech Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02037165 | Jan → Apr 2014 | — | Boehringer Ingelheim | Completed | Missed primary |
| Phase 1 | NCT02326987 | Oct → Nov 2013 | — | GL Pharm Tech Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01808300 | Feb → Jul 2013 | — | Unimed Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02103686 | Nov → Dec 2012 | — | IlDong Pharmaceutical Co Ltd | Completed | No outcome recorded |
| Phase 1 | NCT01443169 | Mar → Apr 2012 | — | Viatris Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01420913 | Aug 2011 | — | Yuhan Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01342198 | Jun → Jul 2011 | — | Viatris Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01321671 | Apr → Jun 2011 | — | Viatris Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01257529 | Mar → Apr 2011 | — | Viatris Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01270815 | Mar → Apr 2011 | — | Viatris Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01291524 | Feb → May 2011 | — | Viatris Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01257516 | Feb → Mar 2011 | — | Viatris Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01220219 | Nov 2010 → Jan 2011 | — | Viatris Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01202435 | Oct → Nov 2010 | — | Viatris Inc. | Completed | Met primary |
| Phase 1 | NCT01202422 | Oct → Nov 2010 | — | Viatris Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01080612 | Apr → Jun 2010 | — | Viatris Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01009541 | Nov → Dec 2009 | — | Viatris Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00760474 | Jan 2009 → Mar 2011 | fibromyalgia | Viatris Inc. | Completed | No outcome recorded |
| Phase 1/24 trials · 1 missed | ||||||
| Phase 1/2 | NCT05442931 | May → Oct 2022 | — | Minia University | Unknown | No outcome recorded |
| Phase 1/2 | NCT02482818 | Sep 2015 → Dec 2021 | — | Ottawa Hospital Research Institute | Unknown | No outcome recorded |
| Phase 1/2 | NCT01333956 | May 2011 → Mar 2013 | — | Hospital for Special Surgery, New York | Completed | Missed primary |
| Phase 1/2 | NCT00437281 | Apr 2007 → Nov 2012 | focal epilepsy | Viatris Inc. | Completed | No outcome recorded |
| Phase 240 trials · 5 met primary · 5 missed | ||||||
| Phase 2 | NCT06614322 | Feb 2026 → Jun 2028 expected | chemotherapy-induced neuropathy, diabetic polyneuropathy, neuropathy, painful | University of Rochester | Recruiting | No outcome recorded |
| Phase 2 | NCT07275762 | Feb → Jul 2026 overdue | postherpetic neuralgia | Neurodawn Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06150898 | May 2025 → Apr 2027 expected | estrogen-receptor positive breast cancer | Jules Bordet Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT06490484 | Apr → Jul 2024 | diabetic polyneuropathy | Haisco Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT05995535 | Jan 2024 → Aug 2026 overdue | substance withdrawal syndrome | University of Pennsylvania | Recruiting | No outcome recorded |
| Phase 2 | NCT05967052 | Oct 2023 → Sep 2025 | long COVID-19, myalgic encephalomeyelitis/chronic fatigue syndrome | National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland | Terminated | No outcome recorded |
| Phase 2 | NCT04173390 | Mar → Dec 2021 | — | InCor Heart Institute | Unknown | No outcome recorded |
| Phase 2 | NCT04322305 | Jan 2021 → Jun 2025 | alcohol dependence | New York State Psychiatric Institute | Suspended | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04218240 | Dec 2020 → Aug 2023 | substance withdrawal syndrome | University of Pennsylvania | Completed | Missed primary |
| Phase 2 | NCT04221165 | Aug 2020 → Sep 2023 | head and neck cancer, mucositis | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Completed | Met primary |
| Phase 2 | NCT04495283 | Jul → Nov 2020 | — | Nevakar, Inc. | Completed | Met primary |
| Phase 2 | NCT05083793 | Apr 2020 → Jan 2022 | — | Assiut University | Unknown | No outcome recorded |
| Phase 2 | NCT04181346 | Sep 2019 → Feb 2020 | — | Faculdade de Medicina do ABC | Unknown | No outcome recorded |
| Phase 2 | NCT03652818 | Jun → Sep 2018 | dental pulp disorder | Nevakar, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03256253 | Feb 2018 → May 2019 | alcohol-related disorders | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 2 | NCT03669081 | Sep 2016 → Sep 2018 | neuropathy, painful | University of Utah | Completed | Met primary |
| Phase 2 | NCT03407430 | Jan 2016 → Jun 2017 | breast cancer, lymphoma | UNC Lineberger Comprehensive Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02607254 | Sep 2015 → Jul 2018 | idiopathic small fibers neuropathy | Johns Hopkins University | Completed | No outcome recorded |
| Phase 2 | NCT02924675 | Jun 2015 → Dec 2018 | ear infection | University Hospital, Lille | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02372578 | May 2015 → May 2016 | diabetic polyneuropathy | Astellas Pharma Global Development, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT02215252 | Nov 2014 → Jul 2015 | diabetic polyneuropathy | Pfizer | Completed | Missed primary |
| Phase 2 | NCT03049605 | Jan 2014 → Jan 2015 | diabetes mellitus | Imam Abdulrahman Bin Faisal University | Completed | No outcome recorded |
| Phase 2 | NCT01821430 | Mar 2013 → Feb 2016 | chronic pain syndrome | Georgetown University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01904097 | Mar 2013 → Jul 2014 | fibromyalgia | Hospital de Clinicas de Porto Alegre | Unknown | No outcome recorded |
| Phase 2 | NCT01637077 | Jan 2012 → Nov 2013 | peripheral neuropathy | Academic and Community Cancer Research United | Completed | Missed primary |
| Phase 2 | NCT01314222 | Mar 2011 → Mar 2012 | diabetic polyneuropathy | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT00929344 | Jul 2009 → Oct 2014 | alcohol dependence | The Scripps Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT00837941 | Apr → Aug 2009 | diabetic polyneuropathy | Merck Sharp & Dohme LLC | Withdrawn | No outcome recorded |
| Phase 2 | NCT00853229 | Feb 2009 → Apr 2013 | vulvitis, vulvodynia | The Cleveland Clinic | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00599638 | Apr → Dec 2008 | postherpetic neuralgia | Pfizer | Completed | Missed primary |
| Phase 2 | NCT00676403 | Apr 2008 → Jan 2009 | restless legs syndrome | Viatris Inc. | Completed | Met primary |
| Phase 2 | NCT00643760 | Mar 2008 → Feb 2009 | diabetic polyneuropathy | XenoPort, Inc. | Completed | Missed primary |
| Phase 2 | NCT00637975 | Sep 2007 → Dec 2010 | cancer | Associazione Progetto Oncologia UMAN.A | Completed | No outcome recorded |
| Phase 2 | NCT00334685 | Aug 2006 → Oct 2007 | — | Pfizer | Terminated | No outcome recorded |
| Phase 2 | NCT00352651 | Jun → Dec 2006 | herpes zoster, postherpetic neuralgia | University of California, San Francisco | Terminated | No outcome recorded |
| Phase 2 | NCT00558753 | Apr 2006 → Jun 2010 | complex regional pain syndrome | Rush University Medical Center | Completed | Met primary |
| Phase 2 | NCT00245609 | Jan → Oct 2006 | — | Viatris Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00746681 | Dec 2005 → Nov 2006 | overactive bladder | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00141414 | Nov 1997 → Oct 2005 | epilepsy | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT01675986 | ? → Nov 2014 | anxiety | Poitiers University Hospital | Completed | No outcome recorded |
| Phase 2/311 trials · 2 met primary | ||||||
| Phase 2/3 | NCT06117917 | Nov 2023 → May 2024 | chronic pain syndrome | Beijing Tiantan Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT05509946 | Oct 2022 → Apr 2023 | — | Indonesia University | Unknown | No outcome recorded |
| Phase 2/3 | NCT05160493 | Dec 2021 → Dec 2023 | chronic pain syndrome | Beijing Tiantan Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT05096468 | Dec 2021 → Jun 2022 | spinal cord neoplasm | Beijing Tiantan Hospital | Completed | Met primary |
| Phase 2/3 | NCT04122196 | Jun 2020 → Jul 2023 | substance dependence, urolithiasis | University of Missouri-Columbia | Completed | No outcome recorded |
| Phase 2/3 | NCT03232021 | Aug 2017 → Dec 2018 | — | Saint Savvas Anticancer Hospital | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT03229668 | Jul 2017 → Dec 2019 | — | Saint Savvas Anticancer Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT02701764 | Jul 2016 → Dec 2018 | dry eye syndrome | University of Miami | Completed | No outcome recorded |
| Phase 2/3 | NCT02639533 | Dec 2014 → Jan 2017 | fibromyalgia | Hospital de Clinicas de Porto Alegre | Completed | Met primary |
| Phase 2/3 | NCT01701921 | Jul 2011 → Feb 2016 | — | Larissa University Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT00370656 | Feb 2007 → May 2009 | diabetes mellitus, peripheral neuropathy | University of Surrey | Completed | No outcome recorded |
| Phase 393 trials · 17 met primary · 17 missed | ||||||
| Phase 3 | NCT07712913 | Jun 2026 → Jun 2027 expected | diabetic neuropathy, neuropathy, painful, postherpetic neuralgia | Brainfarma | Recruiting | No outcome recorded |
| Phase 3 | NCT06383702 | May 2024 → Apr 2025 | diabetic polyneuropathy | CSPC Ouyi Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT06516094 | Apr 2024 → Jan 2025 | chronic pain syndrome | Laboratorios Silanes S.A. de C.V. | Completed | No outcome recorded |
| Phase 3 | NCT06180707 | Jan → Mar 2024 | dentin sensitivity | Federal University of Pará | Unknown | No outcome recorded |
| Phase 3 | NCT05324059 | Jul 2022 → Apr 2023 | neuropathy, painful | Laboratorios Silanes S.A. de C.V. | Completed | No outcome recorded |
| Phase 3 | NCT04517110 | Apr 2021 → Sep 2022 | substance-related disorder | Hamilton Health Sciences Corporation | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT04161027 | Feb 2020 → Apr 2022 | restless legs syndrome | Seoul National University Hospital | Completed | Missed primary |
| Phase 3 | NCT03928093 | Aug 2019 → Mar 2023 | epidermolysis bullosa dystrophica, neuropathy, painful | The Hospital for Sick Children | Completed | Met primary |
| Phase 3 | NCT03927781 | Apr → Oct 2019 | nephrolithiasis | University of Missouri-Columbia | Completed | No outcome recorded |
| Phase 3 | NCT03216187 | Jan 2018 → Jun 2024 | — | Benno Rehberg-Klug | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT02884908 | Jul 2017 → Jan 2022 | alcohol-related disorders, post-traumatic stress disorder | University of Maryland, Baltimore | Completed | Missed primary |
| Phase 3 | NCT02868814 | May 2016 → May 2019 | fibromyalgia | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT03221907 | Apr 2016 → Jan 2019 | mononeuropathy | Daewon Pharmaceutical Co., Ltd. | Completed | Met primary |
| Phase 3 | NCT02868801 | Mar 2015 → Jun 2017 | postherpetic neuralgia | Jiangsu HengRui Medicine Co., Ltd. | Unknown | Met primary |
| Phase 3 | NCT02187471 | Jan 2015 → Jan 2017 | fibromyalgia | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 3 | NCT02374567 | Jan 2015 → Jun 2017 | anxiety disorder, dementia, depressive disorder, schizophrenia +1 | Hannover Medical School | Terminated | No outcome recorded |
| Phase 3 | NCT02240199 | Nov 2014 → Jan 2016 | chronic pain syndrome, myofascial pain syndrome | McMaster University | Completed | No outcome recorded |
| Phase 3 | NCT02072824 | Sep 2014 → Mar 2018 | focal epilepsy | Viatris Inc. | Completed | Mixed |
| Phase 3 | NCT01863810 | Aug 2013 → Oct 2014 | diabetic neuropathy | KunWha Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT01747915 | Apr 2013 → Feb 2019 | epilepsy with generalized tonic-clonic seizures | Viatris Inc. | Completed | Missed primary |
| Phase 3 | NCT03031340 | May → Sep 2012 | — | Montefiore Medical Center | Terminated | No outcome recorded |
| Phase 3 | NCT01463306 | Feb 2012 → Aug 2019 | epilepsy with generalized tonic-clonic seizures, focal epilepsy | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01387607 | Feb 2012 → Oct 2016 | fibromyalgia | Viatris Inc. | Completed | Met primary |
| Phase 3 | NCT01455415 | Dec 2011 → Nov 2013 | diabetic polyneuropathy | Viatris Inc. | Completed | Missed primary |
| Phase 3 | NCT01432236 | Oct 2011 → Jul 2013 | fibromyalgia | Viatris Inc. | Completed | Met primary |
| Phase 3 | NCT01474772 | Oct 2011 → Jul 2013 | diabetic polyneuropathy | Viatris Inc. | Completed | Missed primary |
| Phase 3 | NCT01389596 | Sep 2011 → Aug 2016 | focal epilepsy | Viatris Inc. | Completed | Met primary |
| Phase 3 | NCT01332149 | Jul 2011 → Apr 2014 | diabetic polyneuropathy | Viatris Inc. | Completed | Missed primary |
| Phase 3 | NCT01271933 | Mar 2011 → Jul 2012 | fibromyalgia | Viatris Inc. | Completed | Met primary |
| Phase 3 | NCT01270828 | Mar 2011 → Sep 2014 | postherpetic neuralgia | Viatris Inc. | Completed | Met primary |
| Phase 3 | NCT01262677 | Feb 2011 → Jul 2012 | focal epilepsy | Viatris Inc. | Completed | Missed primary |
| Phase 3 | NCT02927951 | Jan 2011 → Dec 2013 | diabetic polyneuropathy, neuralgia | Eastern Virginia Medical School | Completed | No outcome recorded |
| Phase 3 | NCT01202227 | Sep 2010 → Mar 2012 | neuralgia, spinal cord injury | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01145417 | Jul 2010 → May 2012 | HIV infectious disease, neuropathy, painful | Viatris Inc. | Terminated | Missed primary |
| Phase 3 | NCT01061372 | May 2010 → Aug 2011 | restless legs syndrome | Viatris Inc. | Withdrawn | No outcome recorded |
| Phase 3 | NCT01049217 | Apr 2010 → May 2012 | sensory peripheral neuropathy | Viatris Inc. | Terminated | Missed primary |
| Phase 3 | NCT01057693 | Mar 2010 → Jan 2012 | diabetic polyneuropathy | Viatris Inc. | Completed | Missed primary |
| Phase 3 | NCT01089556 | Mar 2010 → Nov 2011 | diabetic neuropathy | Eli Lilly and Company | Completed | Missed primary |
| Phase 3 | NCT00991276 | Dec 2009 → Jun 2011 | restless legs syndrome | Viatris Inc. | Completed | Met primary |
| Phase 3 | NCT01450345 | Sep 2009 → Dec 2011 | — | University of Malaya | Unknown | No outcome recorded |
| Phase 3 | NCT00830128 | Jul 2009 → Feb 2011 | fibromyalgia | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00883740 | Jun 2009 → Jun 2010 | fibromyalgia, sleep disorder | Viatris Inc. | Completed | Met primary |
| Phase 3 | NCT00819988 | May 2009 → Sep 2011 | delirium | Ottawa Hospital Research Institute | Completed | No outcome recorded |
| Phase 3 | NCT00830167 | Mar 2009 → May 2011 | fibromyalgia | Viatris Inc. | Completed | Met primary |
| Phase 3 | NCT00806026 | Dec 2008 → May 2011 | restless legs syndrome | Viatris Inc. | Completed | Mixed |
| Phase 3 | NCT00729690 | Aug 2008 → Jun 2011 | — | Asokumar Buvanendran | Completed | Missed primary |
| Phase 3 | NCT00702949 | Jun 2008 → Feb 2010 | breast cancer | Alliance for Clinical Trials in Oncology | Completed | Met primary |
| Phase 3 | NCT00596466 | Apr 2008 → Dec 2011 | epilepsy | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00623285 | Apr 2008 → Mar 2011 | — | University of Manitoba | Unknown | No outcome recorded |
| Phase 3 | NCT00553280 | Feb 2008 → Jan 2010 | diabetic polyneuropathy | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00551135 | Jan 2008 → Jun 2009 | neuropathy, painful | Viatris Inc. | Completed | Missed primary |
| Phase 3 | NCT00553475 | Oct 2007 → Mar 2009 | diabetic neuropathy | Viatris Inc. | Completed | Mixed |
| Phase 3 | NCT00524030 | Sep 2007 → Apr 2011 | focal epilepsy | Viatris Inc. | Terminated | Met primary |
| Phase 3 | NCT00468845 | Jun 2007 → May 2010 | neuropathy, painful | Viatris Inc. | Completed | Missed primary |
| Phase 3 | NCT00447369 | May 2007 → Mar 2008 | migraine disorder | Hospital Militar del General Luis Felipe Brieba Aran | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT00448916 | May 2007 → Oct 2013 | epilepsy | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00442546 | May 2007 → Dec 2008 | osteoarthritis | Viatris Inc. | Completed | Missed primary |
| Phase 3 | NCT00372528 | Mar 2007 → Oct 2011 | epilepsy | Viatris Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT00424372 | Jan 2007 → Aug 2008 | postherpetic neuralgia | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00407745 | Jan 2007 → Feb 2011 | neuralgia, spinal cord injury | Viatris Inc. | Completed | Met primary |
| Phase 3 | NCT00346034 | Dec 2006 → Feb 2008 | fibromyalgia | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00413010 | Dec 2006 → Feb 2008 | generalized anxiety disorder | Viatris Inc. | Completed | Met primary |
| Phase 3 | NCT00394901 | Sep 2006 → Nov 2007 | postherpetic neuralgia | Viatris Inc. | Completed | Mixed |
| Phase 3 | NCT00280059 | Aug 2006 → Dec 2009 | focal epilepsy | Viatris Inc. | Completed | Missed primary |
| Phase 3 | NCT00333866 | Jul 2006 → Nov 2007 | fibromyalgia | Viatris Inc. | Completed | Mixed |
| Phase 3 | NCT00264875 | Feb 2006 → Feb 2008 | HIV infectious disease, peripheral neuropathy | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00282997 | Feb → Oct 2006 | fibromyalgia | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00301223 | Feb 2006 → Sep 2007 | neuropathy, painful | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00141219 | Dec 2005 → Dec 2007 | diabetic neuropathy, neuralgia | Viatris Inc. | Completed | Met primary |
| Phase 3 | NCT00219544 | Nov 2005 → Feb 2008 | neuropathy, painful | Viatris Inc. | Completed | Met primary |
| Phase 3 | NCT00232141 | Oct 2005 → Nov 2007 | HIV infectious disease, peripheral neuropathy | Viatris Inc. | Completed | Missed primary |
| Phase 3 | NCT00141258 | Oct 2005 → Aug 2006 | focal epilepsy | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00230776 | Oct 2005 → Jul 2006 | fibromyalgia | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00151489 | Apr 2005 → Jun 2006 | fibromyalgia | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00159705 | Apr 2005 → Jun 2007 | radiculopathy | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00143130 | Apr 2005 → Sep 2007 | epilepsy | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00151450 | Mar 2005 → Nov 2006 | anxiety | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00143156 | Mar 2005 → May 2007 | diabetic neuropathy | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00151528 | Jan 2005 → Jun 2006 | fibromyalgia | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00631943 | Nov 2004 → Mar 2005 | neuralgia | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00645398 | Sep 2004 → Jun 2005 | fibromyalgia | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00643136 | Nov 2002 → Jun 2004 | focal epilepsy | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00141375 | Aug 2002 → Jan 2006 | neuropathy, painful | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00150293 | Mar 2002 → Nov 2005 | focal epilepsy | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00150436 | Feb 2002 → Jul 2005 | neuralgia | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00141362 | Oct 2001 → Aug 2005 | — | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00143143 | Sep 2001 → Feb 2006 | complex partial epilepsy | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00150449 | Jan 2001 → Mar 2006 | anxiety disorder | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00150423 | Jan 2001 → Jul 2005 | diabetic polyneuropathy | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00141336 | Nov 1999 → Jul 2005 | focal epilepsy | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00141401 | Sep 1999 → Jul 2005 | neuropathy, painful | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00141245 | Oct 1998 → Nov 2005 | focal epilepsy | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00141388 | Jul 1998 → Oct 2005 | focal epilepsy | Pfizer | Completed | No outcome recorded |
| Phase 487 trials · 10 met primary · 8 missed | ||||||
| Phase 4 | NCT07795593 | Oct 2026 → May 2031 expected | diabetic kidney disease, diabetic neuropathy | University of Michigan | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07288528 | Apr 2026 → Apr 2029 expected | hypersensitivity reaction disease | McMaster University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07076069 | Jul 2025 → Jun 2028 expected | rotator cuff syndrome | Montefiore Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT06790537 | Apr 2025 → Jun 2026 overdue | — | Post Graduate Institute of Medical Education and Research, Chandigarh | Recruiting | No outcome recorded |
| Phase 4 | NCT07866443 | Mar → Dec 2025 | myofascial pain syndrome | National and Kapodistrian University of Athens | Completed | No outcome recorded |
| Phase 4 | NCT06113211 | Oct 2024 → Sep 2026 overdue | disease of bone structure, substance-related disorder | Henry Ford Health System | Recruiting | No outcome recorded |
| Phase 4 | NCT06367998 | Sep 2024 → May 2025 overdue | neuropathy, painful, rotator cuff syndrome | The Catholic University of Korea | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06401499 | Jun → Oct 2024 | — | Muhammad Ilyas | Unknown | No outcome recorded |
| Phase 4 | NCT07567924 | Feb 2024 → May 2026 | — | Subas Ali | Completed | No outcome recorded |
| Phase 4 | NCT05804591 | Apr 2023 → Apr 2025 overdue | obesity disorder, substance-related disorder | Medical University of Warsaw | Recruiting | No outcome recorded |
| Phase 4 | NCT05460871 | Feb 2023 → Jan 2024 | osteoarthritis, knee | University of Iowa | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT05598905 | Oct 2022 → Jan 2024 | respiratory underresponsiveness to hypoxia and hypercapnia | Leiden University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT05478382 | Oct 2022 → Dec 2025 | — | Ajou University School of Medicine | Unknown | No outcome recorded |
| Phase 4 | NCT05053126 | Jul 2021 → Apr 2022 | substance abuse | Viatris Specialty LLC | Completed | No outcome recorded |
| Phase 4 | NCT05447364 | Jul 2021 → Sep 2023 | osteoarthritis, knee | Thammasat University | Completed | No outcome recorded |
| Phase 4 | NCT04846673 | May 2021 → Nov 2022 | diabetic polyneuropathy | Yuhan Corporation | Completed | Met primary |
| Phase 4 | NCT04705480 | Apr 2021 → Sep 2024 | — | CAMC Health System | Completed | Missed primary |
| Phase 4 | NCT04782310 | Mar → Aug 2021 | — | Cairo University | Unknown | No outcome recorded |
| Phase 4 | NCT04599894 | Nov 2020 → Apr 2021 | neuropathy, painful, osteoarthritis, hip, osteoarthritis, knee | The First Hospital of Jilin University | Completed | No outcome recorded |
| Phase 4 | NCT05624853 | May 2020 → Dec 2022 | neuropathy, painful, type 2 diabetes mellitus | Yuhan Corporation | Completed | Met primary |
| Phase 4 | NCT04246619 | Nov 2019 → Dec 2021 | diabetic polyneuropathy | KRKA | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT04495374 | Sep 2019 → Sep 2020 | neuropathy, painful, opioid abuse | Federal University of Alfenas | Terminated | No outcome recorded |
| Phase 4 | NCT04015908 | Aug 2019 → Jan 2023 | substance-related disorder | University of Utah | Completed | Met primary |
| Phase 4 | NCT03714867 | Mar 2019 → Jul 2020 | head and neck cancer, neuropathy, painful | Augusta University | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT03748290 | Aug 2018 → Nov 2019 | chronic pain syndrome, spinal cord injury | Sheba Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT03584074 | Jul 2018 → May 2019 | lumbar spinal stenosis | Seoul National University Bundang Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04653792 | Jun 2018 → Apr 2020 | lumbar disk disease, neuropathy, painful | Ziauddin University | Completed | No outcome recorded |
| Phase 4 | NCT03712475 | Jan → Sep 2018 | diabetic polyneuropathy, fibromyalgia, focal epilepsy | Yung Shin Pharm. Ind. Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT03456947 | Jan → Jun 2017 | — | Shanghai Zhongshan Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03241875 | Dec 2016 → Aug 2017 | gallbladder disorder, neuropathy, painful | Faculty of Medicine, Sousse | Completed | Met primary |
| Phase 4 | NCT02747940 | Dec 2015 → Dec 2019 | fibromyalgia, migraine disorder | Taipei Veterans General Hospital, Taiwan | Completed | No outcome recorded |
| Phase 4 | NCT02260388 | Oct 2014 → Sep 2017 | idiopathic progressive polyneuropathy | University of Kansas Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01852318 | Apr 2014 → May 2015 | — | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03017430 | Jan 2014 → Dec 2019 | substance withdrawal syndrome | St. Petersburg Bekhterev Research Psychoneurological Institute | Completed | No outcome recorded |
| Phase 4 | NCT01838044 | Oct 2013 → May 2015 | neuropathy, painful | Viatris Inc. | Terminated | Missed primary Stop: Enrollment |
| Phase 4 | NCT01591980 | Aug 2013 → Aug 2014 | chronic pain syndrome, headache disorder | Unity Health Toronto | Withdrawn | No outcome recorded |
| Phase 4 | NCT01801189 | Feb 2013 → Dec 2015 | — | Legacy Health System | Completed | Missed primary |
| Phase 4 | NCT02205879 | Jan 2013 → Dec 2019 | alcohol dependence | St. Petersburg Bekhterev Research Psychoneurological Institute | Completed | No outcome recorded |
| Phase 4 | NCT01727791 | Dec 2012 → Aug 2013 | — | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT01770964 | Dec 2012 → Jul 2013 | diabetes mellitus, diabetic polyneuropathy | Analgesic Solutions | Unknown | No outcome recorded |
| Phase 4 | NCT02180880 | Nov 2012 → Aug 2014 | neuralgia, spinal cord injury | Ju Seok Ryu | Completed | No outcome recorded |
| Phase 4 | NCT01603394 | Oct 2012 → Jun 2013 | postherpetic neuralgia | Pfizer | Terminated | No outcome recorded |
| Phase 4 | NCT01768988 | Aug 2012 → Dec 2017 | malignant pancreatic neoplasm | Parc de Salut Mar | Terminated | No outcome recorded |
| Phase 4 | NCT01298466 | Feb 2012 → Feb 2013 | neuralgia | Viatris Inc. | Withdrawn | No outcome recorded |
| Phase 4 | NCT01419405 | Dec 2011 → Mar 2012 | — | Oslo University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01455428 | Dec 2011 → Jan 2014 | postherpetic neuralgia | Viatris Inc. | Completed | Met primary |
| Phase 4 | NCT01397006 | Sep 2011 → Mar 2014 | fibromyalgia | Newton-Wellesley Hospital | Withdrawn | No outcome recorded |
| Phase 4 | NCT01020526 | Sep 2010 → Jun 2015 | fibromyalgia | Viatris Inc. | Completed | Missed primary |
| Phase 4 | NCT01020474 | May 2010 → Dec 2014 | fibromyalgia | Viatris Inc. | Completed | Missed primary |
| Phase 4 | NCT01158859 | Apr 2010 → Aug 2011 | — | University of Sherbrooke | Completed | Missed primary |
| Phase 4 | NCT01073501 | Apr 2010 → Mar 2012 | — | Shaare Zedek Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT01128712 | Apr 2010 → Jul 2014 | complex partial epilepsy | Northeast Regional Epilepsy Group | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01094808 | Mar 2010 → Feb 2011 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 4 | NCT01059331 | Feb 2010 → Oct 2011 | — | Oslo University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01309074 | Nov 2009 → Dec 2012 | anxiety, epilepsy | Rush University Medical Center | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01242332 | Aug 2009 → Oct 2010 | — | Prince of Songkla University | Completed | No outcome recorded |
| Phase 4 | NCT00938548 | Jun → Dec 2009 | neuropathy, painful | Severance Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00624780 | May 2009 → Apr 2012 | generalized anxiety disorder | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00905580 | May → Sep 2009 | neuropathy, painful | Severance Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00994786 | Jan 2009 → Jan 2019 | obsessive-compulsive disorder | McMaster University | Completed | No outcome recorded |
| Phase 4 | NCT00785382 | Jan 2009 → Dec 2011 | — | IWK Health Centre | Completed | No outcome recorded |
| Phase 4 | NCT00781131 | May 2008 → Jul 2010 | — | IWK Health Centre | Completed | Missed primary |
| Phase 4 | NCT00791739 | Apr 2008 → Jul 2009 | fibromyalgia | University of Granada | Completed | No outcome recorded |
| Phase 4 | NCT00663962 | Apr → Nov 2008 | chronic pain syndrome | Queen's University | Completed | No outcome recorded |
| Phase 4 | NCT00638443 | Mar 2008 → Mar 2010 | lumbar spinal stenosis | University of Rochester | Completed | No outcome recorded |
| Phase 4 | NCT00631696 | Feb 2008 → Feb 2012 | — | Viatris Inc. | Completed | Met primary |
| Phase 4 | NCT01061697 | Jan 2008 → Mar 2010 | radiculopathy, spondylosis, cervical | Singapore General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00584246 | Nov 2007 → May 2008 | restless legs syndrome | University of South Florida | Withdrawn | No outcome recorded |
| Phase 4 | NCT00855738 | May 2007 → Jun 2009 | focal epilepsy | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00407797 | Mar 2007 → Aug 2009 | focal epilepsy | Viatris Inc. | Terminated | Met primary |
| Phase 4 | NCT00407511 | Jan 2007 → Jul 2008 | chemotherapy-induced neuropathy, diabetic polyneuropathy, neuropathy, painful, postherpetic neuralgia | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00380874 | Jan 2007 → Mar 2008 | chemotherapy-induced neuropathy | Viatris Inc. | Terminated | Missed primary |
| Phase 4 | NCT00381095 | Dec 2006 → Oct 2010 | bone neoplasm, cancer, chronic pain syndrome | Viatris Inc. | Terminated | No outcome recorded |
| Phase 4 | NCT00351611 | Jul 2006 → Feb 2020 | focal epilepsy | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00310583 | Jul 2006 → Apr 2008 | neuropathy, painful | Professional Associations Clinic Bergmannsheil | Unknown | No outcome recorded |
| Phase 4 | NCT00573261 | Mar 2006 → May 2008 | diabetic polyneuropathy | Duke University | Completed | Met primary |
| Phase 4 | NCT00292188 | Jan 2006 → May 2008 | neuralgia | Viatris Inc. | Completed | Met primary |
| Phase 4 | NCT00378547 | Jan 2006 → Dec 2009 | — | Glostrup University Hospital, Copenhagen | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00288639 | Dec 2005 → Dec 2007 | epilepsy | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00235261 | Oct 2005 → Jun 2007 | — | Glostrup University Hospital, Copenhagen | Completed | No outcome recorded |
| Phase 4 | NCT00209495 | Jun 2005 → Nov 2007 | neuropathy, painful | Glostrup University Hospital, Copenhagen | Completed | No outcome recorded |
| Phase 4 | NCT00156078 | Jan 2005 → May 2007 | diabetic polyneuropathy | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00159731 | Jan 2005 → May 2006 | diabetic polyneuropathy | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00141427 | Nov 2004 → May 2006 | epilepsy | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00629681 | Nov 2004 → Feb 2006 | peripheral neuropathy | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00159666 | Oct 2004 → Jun 2006 | postherpetic neuralgia | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00159679 | Sep 2004 → Oct 2005 | diabetic neuropathy | Viatris Inc. | Completed | Met primary |
| Phase not applicable36 trials · 2 met primary · 1 missed | ||||||
| — | NCT07549490 | Oct 2026 → Dec 2029 expected | — | National Center for Complementary and Integrative Health (NCCIH) | Not yet recruiting | No outcome recorded |
| — | NCT07818577 | Oct 2026 → Jun 2027 expected | chronic pain syndrome | Beijing Tiantan Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07630753 | May → Dec 2026 expected | intracranial hypertension | Benha University | Active not recruiting | No outcome recorded |
| — | NCT07635394 | Apr 2026 overdue | irritable bowel syndrome | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
| — | NCT07683338 | Feb → Apr 2026 | diabetic polyneuropathy | Syeda Khatoon e Jannat Welfare Foundation | Completed | No outcome recorded |
| — | NCT07606638 | Feb → Jul 2026 overdue | oral cavity squamous cell carcinoma | Mayo Hospital Lahore | Enrolling by invitation | No outcome recorded |
| — | NCT07344467 | Jan 2026 → Jun 2027 expected | anxiety | Tanta University | Recruiting | No outcome recorded |
| — | NCT07598474 | Jan → Jul 2026 overdue | osteoarthritis, knee | University of Faisalabad | Recruiting | No outcome recorded |
| — | NCT07389551 | Jul → Dec 2025 | — | Muhammad Aamir Latif | Completed | No outcome recorded |
| — | NCT06420778 | Jul 2024 → Jun 2025 | postherpetic neuralgia | Zhejiang Chinese Medical University | Unknown | No outcome recorded |
| — | NCT06357260 | Apr 2024 → Feb 2025 | trigeminal neuralgia | Postgraduate Institute of Dental Sciences Rohtak | Unknown | No outcome recorded |
| — | NCT06300346 | Mar → Aug 2024 | — | Sohag University | Unknown | No outcome recorded |
| — | NCT05704374 | Nov → Dec 2023 | fibromyalgia | Istanbul Physical Medicine Rehabilitation Training and Research Hospital | Unknown | No outcome recorded |
| — | NCT05795478 | Oct 2023 → Dec 2024 overdue | chronic pain syndrome | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
| — | NCT06155916 | Nov 2022 → Dec 2025 overdue | insomnia, neuropathy, painful | Helsinki University Central Hospital | Recruiting | No outcome recorded |
| — | NCT05322681 | May 2022 → May 2023 | osteoarthritis | The Catholic University of Korea | Unknown | No outcome recorded |
| — | NCT05254652 | May 2022 → May 2023 | osteoarthritis | The Catholic University of Korea | Unknown | No outcome recorded |
| — | NCT05248152 | Jan 2022 → Jan 2024 | — | University Medical Centre Ljubljana | Unknown | No outcome recorded |
| — | NCT06066918 | Jul 2021 → Feb 2026 overdue | spinal cord injury | Loewenstein Hospital | Recruiting | No outcome recorded |
| — | NCT04478526 | Apr 2020 → May 2021 | generalized anxiety disorder | Dr. Nazanin Alavi | Completed | No outcome recorded |
| — | NCT03721432 | May → Nov 2018 | benign shuddering attacks | Beni-Suef University | Completed | No outcome recorded |
| — | NCT03211728 | Jul 2017 → Feb 2019 | — | Yonsei University | Completed | No outcome recorded |
| — | NCT03603626 | Sep 2015 → Dec 2017 | chronic purulent otitis media | Dhulikhel Hospital | Withdrawn | No outcome recorded |
| — | NCT02394951 | Apr 2015 → Apr 2018 | peripheral neuropathy | Washington University School of Medicine | Completed | No outcome recorded |
| — | NCT02340455 | Dec 2014 → Nov 2016 | — | Yonsei University | Withdrawn | No outcome recorded |
| — | NCT02277548 | May 2014 → Apr 2018 | head and neck squamous cell carcinoma, oropharynx cancer | Abramson Cancer Center at Penn Medicine | Completed | No outcome recorded |
| — | NCT01612832 | Jun 2012 → Jun 2013 | — | Tel-Aviv Sourasky Medical Center | Unknown | Met primary |
| — | NCT01528540 | Apr 2012 → Dec 2014 | chronic pancreatitis | Asian Institute of Gastroenterology, India | Completed | No outcome recorded |
| — | NCT01370915 | Sep 2010 → Nov 2011 | anterior deviation infundibular septum | Samsung Medical Center | Unknown | No outcome recorded |
| — | NCT00967135 | Jun 2010 → Apr 2012 | neuropathy, painful | University of Montreal Hospital Centre (CHUM) | Completed | No outcome recorded |
| — | NCT01097577 | Mar → Jun 2010 | — | 59th Medical Wing | Completed | Missed primary |
| — | NCT00954187 | Nov 2009 → Sep 2012 | — | Loma Linda University | Terminated | No outcome recorded |
| — | NCT01366196 | Oct 2008 → Feb 2012 | — | Hospital for Special Surgery, New York | Completed | No outcome recorded |
| — | NCT00610155 | Sep 2008 → Jul 2010 | — | Viatris Inc. | Completed | No outcome recorded |
| — | NCT00891397 | Nov 2007 → Jan 2010 | complex regional pain syndrome type 1 | McMaster University | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT00978341 | Feb 2007 → Oct 2008 | spinal cord injury | Viatris Inc. | Terminated | Met primary |
| Phase not stated1 trial | ||||||
| — | NCT03419949 | — | — | Assiut University | Available | No outcome recorded |
| Comparator or background therapy228 trials | ||||||
| Phase 0 | NCT07400471 Comparator | Feb 2026 → Mar 2027 expected | — | Chattogram International Dental College | Recruiting | No outcome recorded |
| Phase 0 | NCT07016451 Background | Apr 2024 → Sep 2025 | radiation cystitis | Ramathibodi Hospital | Completed | No outcome recorded |
| Phase 0 | NCT05829148 Comparator | May 2023 → Nov 2024 | — | Egymedicalpedia | Unknown | No outcome recorded |
| Phase 0 | NCT05150795 Comparator | Jan 2022 → Dec 2026 expected | — | Ain Shams University | Recruiting | No outcome recorded |
| Phase 0 | NCT03473093 Comparator | Mar 2018 → Mar 2019 | — | Assiut University | Unknown | No outcome recorded |
| Show all 228 trials opens the full record — a long page | ||||||
News releases announcing trial results or a regulatory action · 26
| Date | Issuer | Release |
|---|---|---|
| 2023-10-18 | Hoffmann-La Roche | Regulatory Roche IL-6 is the first immunoassay approved to aid sepsis diagnosis in newborns roche.com ↗
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Elecsys IL-6 immunoassay has become the first IL-6 test to have a certified claim for use in diagnosis of neonatal sepsis, in countries accepting the CE Mark.* |
| 2023-04-13 | Hoffmann-La Roche | Results Roche data highlights strength of ophthalmology portfolio and commitment to advancing eye care at ARVO 2023 roche.com ↗
Additionally, phase I data for an investigational anti-interleukin-6 (IL-6) treatment in uveitic macular edema (UME), to be presented for the first time, suggest the monoclonal antibody may improve visual acuity in patients with UME. |
| 2023-04-12 | Genentech, Inc. | Results Genentech Data Highlights Strength of Ophthalmology Portfolio and Commitment to Advancing Eye Care at ARVO 2023 gene.com ↗
Additionally, Phase I data for an investigational anti-interleukin-6 (IL-6) treatment in uveitic macular edema (UME), to be presented for the first time, suggest the monoclonal antibody may improve visual acuity in patients with UME. |
| 2022-12-10 | Zydus Lifesciences Limited | Regulatory Zydus receives two final approvals from the USFDA for Silodosin capsules and Pregabalin capsules zyduslife.com ↗
The company also received the final approval to market Pregabalin Capsules, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, and 300 mg (USRLD: Lyrica capsules). |
| 2022-12-01 | Alembic Pharmaceuticals Ltd. | Regulatory 22nd December, 2022, Vadodara, India alembicpharmaceuticals.com ↗
This is the first product approval from Jarod Facility which was inspected in Dec 2022. |
| 2022-08-31 | Zydus Lifesciences Limited | Regulatory Zydus receives two final approvals from the USFDA zyduslife.com ↗
The company also received the final approval from USFDA to market Pregabalin Extended-Release Tablets, USP 82.5 mg, 165 mg and 330 mg. |
| 2022-05-06 | Lupin Limited | Regulatory Lupin Receives Approval from U.S. FDA for Pregabalin Capsules lupin.com ↗
Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Pregabalin Capsules, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg to market a generic equivalent of Lyrica® Capsules, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg of Upjohn US 2 LLC. |
| 2022-03-25 | Hoffmann-La Roche | Results Roche to present data across broad and impactful neuroscience portfolio at 2022 AAN Annual Meeting roche.com ↗
Evrysdi data continue to demonstrate long-term efficacy and safety in a broad population of people with spinal muscular atrophy |
| 2021-06-08 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - "PREGABALIN CAPSULES" OBTAINS DRUG REGISTRATION APPROVAL irasia.com ↗
has obtained drug registration approval granted by the National Medical Products Administration of the People’s Republic of China |
| 2020-08-18 | Upsher-Smith Laboratories | Regulatory Sawai Receives Approvals for 4 Generic Drugs with 13 Strengths upsher-smith.com ↗
Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Kenzo Sawai) received approvals by the Ministry of Health, Labour and Welfare for 4 generic drugs with 13 strengths. |
| 2019-12-30 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - THE GROUP'S "PREGABALIN CAPSULES" WAS GRANTED THE U.S. ANDA APPROVAL irasia.com ↗ |
| 2019-07-22 | Impax Laboratories, LLC | Regulatory Amneal Announces Launch of Generic Lyrica® amneal.com ↗
Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that it has received approval for, and launched, its generic version of Lyrica ® (pregabalin capsules) 25 mg, 50 mg, 75, mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg. |
| 2019-05-30 | VistaGen Therapeutics, Inc. | Results VistaGen Announces Positive Preclinical Data Supporting AV-101's Potential for Treating Neuropathic Pain Comparable to Pregabalin (Lyrica(R)), without its Side Effects vistagen.com ↗
This work demonstrated that AV-101 had a significant dose-response with similar efficacy in a rat model of a mononeuropathy as compared to pregabalin (Lyrica), which was used as an active comparator. |
| 2019-05-24 | Pfizer | Results Pfizer Announces Top-Line Results from Phase 3 Trial of LYRICA® (pregabalin) in Primary Generalized Tonic-Clonic Seizures pfizer.com ↗
Treatment with LYRICA did not result in a statistically significant reduction in seizure frequency versus placebo. |
| 2018-12-15 | Zydus Lifesciences Limited | Regulatory Zydus receives approvals from the USFDA for Albendazole Tablets and Pregabalin Capsules zyduslife.com ↗
The group also received a tentative approval for Pregabalin Capsules (US RLD – Lyrica) in the strengths of 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg. |
| 2018-11-27 | Pfizer | Regulatory Pfizer Receives Six Months Pediatric Exclusivity for LYRICA® (pregabalin) pfizer.com ↗
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted pediatric exclusivity for LYRICA ® . |
| 2018-05-17 | Pfizer | Results LYRICA® (pregabalin) Oral Solution CV Phase 3 Trial in Pediatric Epilepsy Meets Primary Endpoint pfizer.com ↗
Results showed that adjunctive treatment with LYRICA 14 mg/kg/day resulted in a statistically significant reduction in seizure frequency versus placebo, the primary efficacy endpoint. |
| 2017-10-12 | Pfizer | Regulatory U.S. FDA Approves LYRICA® CR (pregabalin) Extended-Release Tablets CV pfizer.com ↗
Pfizer Inc. (NYSE: PFE) announced today that the United States Food and Drug Administration (FDA) has approved LYRICA® CR (pregabalin) extended-release tablets CV as once-daily therapy for the management of neuropathic pain associated with diabetic peripheral neuropathy (pDPN) and the management of postherpetic neuralgia (PHN). |
| 2017-02-21 | Eisai Inc. | Regulatory APPROVAL RECEIVED FOR PAIN TREATMENT LYRICA® OD TABLET FORMULATION IN JAPAN eisai.com ↗
Pfizer Japan Inc. (Headquarters: Tokyo, President and Representative Director: Ichiro Umeda,“Pfizer”) announced today that it received marketing and manufacturing approval in Japan on February 17 for Lyrica® OD Tablets 25mg, 75mg, 150mg (OD tablet: orally disintegrating tablet), a new formulation following pain treatment Lyrica Capsules (pregabalin). |
| 2016-12-01 | Pfizer | Results LYRICA® (pregabalin) Phase 3 Trial in Pediatric Epilepsy Meets Primary Endpoint pfizer.com ↗
Pfizer Inc. (NYSE:PFE) announced today positive top-line results of a study that evaluated the use of LYRICA® (pregabalin) Capsules CV and Oral Solution CV as adjunctive therapy for pediatric epilepsy patients four to 16 years of age with partial onset seizures. |
| 2015-11-25 | Pfizer | Results Pfizer Reports Top-Line Results from a Phase 3 Study of LYRICA® (pregabalin) Capsules CV in Adults with Post-Traumatic Peripheral Neuropathic Pain pfizer.com ↗
Pfizer Inc. (NYSE:PFE) announced today top-line results of a Phase 3 study evaluating the efficacy and safety of LYRICA ® (pregabalin) Capsules CV in adults with chronic post-traumatic peripheral neuropathic pain. |
| 2015-03-12 | Pfizer | Results Pfizer Reports Top-Line Results From A Phase 4 Study Evaluating LYRICA® Capsules CV As A Treatment For Adolescents With Fibromyalgia pfizer.com ↗
Pfizer Inc. (NYSE:PFE) announced today top-line results of a double-blind Phase 4 study evaluating the safety and efficacy of Lyrica® (pregabalin) Capsules CV in adolescents (ages 12-17 years) with fibromyalgia (FM). |
| 2013-02-28 | Eisai Inc. | Regulatory NEW INDICATION APPROVED IN JAPAN FOR LYRICA® CAPSULES eisai.com ↗ |
| 2012-06-22 | Eisai Inc. | Regulatory Lyrica® Capsules Approved in Japan for Additional Indication of Pain Associated with Fibromyalgia eisai.com ↗
Pfizer Japan Inc. (Headquarters: Tokyo, President: Ichiro Umeda, “Pfizer”) announced today that it has received approval to market Lyrica® Capsules (pregabalin, “Lyrica”) in Japan for the additional indication of pain associated with fibromyalgia. |
| 2010-10-27 | Eisai Inc. | Regulatory New Indication Approved for Lyrica® Capsules eisai.com ↗
received approval to replace the indication of “postherpetic neuralgia” that is currently approved for Lyrica® Capsules (generic name: pregabalin; hereinafter “Lyrica®”) in Japan with the new and broader indication of “peripheral neuropathic pain.” |
| 2010-04-16 | Eisai Inc. | Regulatory Lyrica® has been approved for treatment of postherpetic neuralgia eisai.com ↗
Pfizer Japan Inc. (Head Office: Tokyo; President: Ichiro Umeda) announced that Lyrica® Capsules (generic name: pregabalin) has been approved today in Japan for the treatment of postherpetic neuralgia. |
All press releases naming this drug 28 releases
Evidence & citations 30 cited values
Every value below carries the sentence it was read from. 549 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pregabalin | “Drugs from ACT groups N03A, N05BA, N05CD, H02A or S01EC will be used including prednisolon,levetiracetam, valproate, carbamazepine, oxcarbazepine, topiramate, felbamate,...” NCT00552526 ↗536“PURPOSE: This study compared the efficacy and safety of controlled-release pregabalin (GLA5PR GLARS-NF1 tablets) with those of an immediate-release pregabalin capsule after 12...” PMID 33272643 ↗ Nov 2020 “Antiepileptic drugs allowed are therefore: lamotrigine, levetiracetam, lacosamide, sodium valproate, carbamazepine, oxcarbabazepine, slicarbazepine, pregabalin, gabapentin,...” NCT03636958 ↗ “Pregabalin is an anticonvulsant agent approved by the United States Food and Drug Administration (FDA) for the treatment of neuropathic pain associated with post-herpetic...” NCT01391858 ↗ “Standard multimodal analgesia including acetaminophen, non-steroidal anti-inflammatory drugs, pregabalin, optional amitriptyline, and opioid analgesics as needed according to...” NCT07863921 ↗ “The Pregabalin group will receive an oral bolus dose of 300 mg of pregabalin up to two hours prior to the procedure and a 75 mg dose every 12 hours for up to 48 hours following...” NCT01789216 ↗ “If never taken SSRI or SNRI, commence primary medication arm (SSRI: sertraline, escitalopram or Pregabalin/SNRI: duloxetine, venlafaxine) will be described to patient and will...” NCT04478526 ↗ “Patients will receive conservative treatment Acetaminophen (paracetamol) 1000 mg tid and pregabalin (lyrica) 75 mg bid; can be increased to 150 mg bid, oxycodone (oxynorm) 10mg IR PRN.” NCT07095569 ↗ “The basic treatment consisted of penciclovir 0.5g/time per day intravenously, mecobalamin 0.5mg/time three times a day orally and pregabalin 75mg/time twice a day orally for 10 days.” NCT06985589 ↗ “A Open-label, Radomized, Crossover Clinical Trial to Assess the Pharmacokinetics of Pregabalin CR After Multiple Dosing as Compared to Pregabalin IR in Healthy Male Volunteers” NCT02783183 ↗ “The drugs included in the treatment plan are morphine (60 mg/day), pregabalin (150 mg/day) and duloxetine (60 mg/day), available free of charge to the participating patients.” NCT05558397 ↗ |
| Known as | averopreg | “Aim of the work: To compare the efficacy of pregabalin agent (averopreg) alone versus combined pregabalin and serotonin norepinephrine reuptake inhibitor (milnacipran) in the...” NCT03905486 ↗ |
| Known as | Brillior | “1 tab of Pregabalin Brillior 75 mg and 1 tab of Placebo” NCT05447364 ↗ |
| Known as | CI-1008 | “Pregabalin (CI-1008,Lyrica) is a chemical analogue of the mammalian neurotransmitter gamma-aminobutyric acid (GABA),although it does not bind to or activates GABA receptors or...” NCT01128712 ↗4“Randomized, Double-Blind, Multicenter, Placebo-Controlled Study To Evaluate Efficacy And Safety Of Pregabalin (CI-1008) In The Treatment For Pain Associated With Diabetic...” NCT00553475 ↗ “A 13 Week, Double-Blind, Placebo-Controlled Phase 4 Trial of Pregabalin (CI-1008, 600 mg/Day) for Relief of Pain in Subjects With Painful Diabetic Peripheral Neuropathy” NCT00159679 ↗ “Randomized, Double-Blind, Multicenter, Placebo-Controlled Study To Evaluate Efficacy And Safety Of Pregabalin（CI-1008）In The Treatment Of Fibromyalgia” NCT00830167 ↗ “An Open Label Extension Safety Trial of Pregabalin (CI-1008) in Subjects With Diabetic Peripheral Neuropathy” NCT00159731 ↗ |
| Known as | GLA5PR GLARS-NF1 | “PURPOSE: This study compared the efficacy and safety of controlled-release pregabalin (GLA5PR GLARS-NF1 tablets) with those of an immediate-release pregabalin capsule after 12...” PMID 33272643 ↗ Nov 20201“Comparative Pharmacokinetics of a Controlled-release Pregabalin Tablet (GLA5PR GLARS-NF1) and an Immediate-release Pregabalin Capsule in Healthy Male Volunteers.” PMID 30497798 ↗ Nov 2018 |
| Known as | Immediate release capsule(lyrica 150mg * 2/day) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02103647 ↗ |
| Known as | Lyrica | “A Phase 4 Randomized Double-Blind Double-Dummy Placebo & Active-Controlled Single-Dose Six-Way Crossover Study Evaluating the Abuse Potential of Lyrica® Taken Orally With...” NCT05053126 ↗62“Pregabalin 25 mg (Lyrica; Pfizer, Germany) or placebo will be administered orally daily at the end of hemodialysis sessions in dialysis patients or every evening in non...” NCT01073501 ↗ “A Randomized, Comparative, Double-Blind, Parallel-Group, Multicenter, Monotherapy, Study Of Pregabalin (Lyrica) And Lamotrigine (Lamictal) In Patients With Newly Diagnosed...” NCT00280059 ↗ “Patients will receive conservative treatment Acetaminophen (paracetamol) 1000 mg tid and pregabalin (lyrica) 75 mg bid; can be increased to 150 mg bid, oxycodone (oxynorm) 10mg IR PRN.” NCT07095569 ↗ “BACKGROUND: Pregabalin (Lyrica(®)) is approved as an immediate-release (IR) formulation for administration twice (BID) or three times (TID) a day depending on indication.” PMID 25078977 ↗ Sep 2014 “Pregabalin (Lyrica) is an anticonvulsant drug with membrane stabilizing and anti-nociceptive effects commonly used for neuropathic pain relief and anxiety disorder.” NCT01359085 ↗ “Pharmacotherapy：① Pregabalin ( Lyrica™ ，Pfizer Inc. America) ② Methylcobalamin ( Mecobalamin tablets， Weicai (China) Pharmaceutical Co., Ltd， China）” NCT06990854 ↗ “Comparatively assess the effectiveness and safety profile of pregabalin (Lyrica) and paroxetine (Paxil) in managing MS-induced neuropathic pain.” NCT00291148 ↗ “Pregabalin is a drug marketed as Lyrica™ in the United States for the treatment of seizures, diabetic neuropathy, and post-herpetic neuralgia.” NCT00352651 ↗ “The purpose of this trial to compare the pharmacokinetic characteristics of YNP-1807(Pregabalin 330mg) and Lyrica capsule(Pregabalin 150mg).” NCT03261427 ↗ “The purpose of this trial to compare the pharmacokinetic characteristics of YHD1119(Pregabalin 300mg) and Lyrica capsule(Pregabalin 150mg).” NCT02783183 ↗ |
| Known as | LYRICA (pregabalin) | “LYRICA (pregabalin)” NCT01928381 ↗ |
| Known as | Lyrica (Pregabalin) 75mg | “Lyrica (Pregabalin) 75mg” NCT04653792 ↗ |
| Known as | Lyrica 150 milligram | “Lyrica 150 milligram” NCT03049605 ↗ |
| Known as | Lyrica capsule | “Lyrica capsule(Pregabalin 150mg)” NCT01420913 ↗ |
| Known as | PGB | “45 patients will be assigned into each group, by order of their recruitment. Third of the patients in each group will be randomized to Duloxetine (DUL), third to Pregabalin...” NCT02672202 ↗5“The objective of this study was to evaluate the anxiolytic efficacy, and speed of onset of efficacy, of pregabalin (PGB) and venlafaxine-XR (VXR) in patients with generalized...” PMID 21456104 ↗ Mar 2009 “Individuals scheduled for surgery, who are pain free, will be assigned to 3 arms - (1) duloxetine (DUL) (SNRI), (2) pregabalin (PGB) (Ca++ channel ligand) and (3) placebo.” NCT02020122 ↗ “A Multi-site, Double-blind, Randomized, Placebo-controlled, Crossover Study of Pregabalin (Lyrica, PGB) in the Treatment of Essential Tremor” NCT00584376 ↗ “Pregabalin (PGB) is an α2 δ calcium-channel subunit ligand that has previously been shown to reduce chronic pain in multiple conditions.” PMID 26816332 ↗ Jun 2016 “Pregabalin (PGB) (Lyrica(®) ; Pfizer Inc.) was used as an active control to provide assay sensitivity of the trial.” PMID 23186035 ↗ Nov 2012 |
| Known as | PGB-CR | “OBJECTIVES: To assess the efficacy and tolerability of add-on pregabalin controlled-release formulation (PGB-CR) (doses of 165 or 330 mg/day) in patients with partial-onset...” PMID 24962242 ↗ Jun 2014 |
| Known as | PGL | “OBJECTIVE The aim of this study was to assess in-hospital (immediate) postoperative pain scores and analgesic consumption (primary goals) and preoperative anxiety and sleep...” PMID 26871201 ↗ Feb 20162“Pregabalin (PGL) (S+ 3-isobutyl GABA), a structural analog of GABA (Gamma-Aminobutyric Acid) and a derivative of gabapentin in various pain settings, including postoperative pain.” NCT01359059 ↗ “effects of pregabalin (PGL) (S+ 3-isobutyl GABA), a structural analog of GABA and a derivative of gabapentin” NCT01614236 ↗ |
| Known as | Preg (Lyrica) | “Preg (Lyrica®)” NCT05389150 ↗ |
| Known as | Pregabalin ER | “A: Pregabalin ER tablet formulation, Target release rate, 1 x 330 mg, Oral.” NCT02725112 ↗ |
| Known as | Pregabalin IR | “D: Pregabalin IR capsule formulation, 1 x 300 mg, Oral.” NCT02725112 ↗ |
| Known as | Pregabalin Krka | “Pregabalin Krka (pregabalin) hard capsules of different strenghts: 25 mg, 75 mg, 150 mg, 300 mg.” NCT04246619 ↗ |
| Known as | Pregabalin XR | “Pregabalin XR: extended-release tablet, with an initial dose of 82.5 mg once daily.” NCT07712913 ↗ |
| Known as | Pregabalin: Lyrica | “Pregabalin: Lyrica” NCT01344213 ↗ |
| Known as | S+ 3-isobutyl GABA | “Pregabalin (PGL) (S+ 3-isobutyl GABA), a structural analog of GABA (Gamma-Aminobutyric Acid) and a derivative of gabapentin in various pain settings, including postoperative pain.” NCT01359059 ↗1“effects of pregabalin (PGL) (S+ 3-isobutyl GABA), a structural analog of GABA and a derivative of gabapentin” NCT01614236 ↗ |
| Known as | S-aminomethyl-5-methylhexaninacid | “Pregabalin (S-aminomethyl-5-methylhexaninacid) is a further development of gabapentin.” NCT00353704 ↗ |
| Known as | YHD1119 | “A new sustained-release (SR) pregabalin formulation (YHD1119) designed for once-daily dosing has recently been developed to improve patient adherence.” PMID 34256964 ↗ Jul 20211“YHD1119 (Pregabalin 300mg)” NCT02783638 ↗ |
| Known as | YHD1119 A | “YHD1119 A(Pregabalin SR 300mg)” NCT01420913 ↗ |
| Known as | YHD1119 B | “YHD1119 B(Pregabalin SR 300mg)” NCT01420913 ↗ |
| Known as | YHD1119 C | “YHD1119 C(Pregabalin SR 300mg)” NCT01420913 ↗ |
| Known as | YNP-1807 | “The purpose of this trial to compare the pharmacokinetic characteristics of YNP-1807(Pregabalin 330mg) and Lyrica capsule(Pregabalin 150mg).” NCT03261427 ↗ |
| Action | Inhibit | “by reducing calcium influx through high-voltage-activated calcium channels containing the alpha2/delta subunit” NCT01359085 ↗ |
| Modality | Small molecule | “Pregabalin is a small molecule” NCT02024568 ↗ |
| Route | Oral | “75 mg oral pregabalin” PMID 21889410 ↗ Aug 2011 |